{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:14:57Z","timestamp":1789906497541,"version":"4.0.1"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.virusres.2015.10.021","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T17:09:07Z","timestamp":1445879347000},"page":"174-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Recent advances in the development of vaccines for Ebola virus disease"],"prefix":"10.1016","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5491-6271","authenticated-orcid":false,"given":"Elijah Ige","family":"Ohimain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.virusres.2015.10.021_bib0005","doi-asserted-by":"crossref","first-page":"48","DOI":"10.9790\/0837-191044856","article-title":"The effects of Ebola virus on the economy of West Africa through the trade channel","volume":"19","author":"Adegun","year":"2014","journal-title":"IOSR J. Humanit. Soc. Sci."},{"key":"10.1016\/j.virusres.2015.10.021_bib0010","unstructured":"ADI, 2014. Ebola and Marburg virus vaccine Elisa Kits, recombinant protein and antibodies. Alpha Diagnostic Laboratories. USA. pp. 1\u20138. <https:\/\/4adi.com\/objects\/catalog\/product\/extras\/AE-320800-Ebola-virus-antigen-elisa-kit.pdf\/> (accessed 9.10.15.)."},{"key":"10.1016\/j.virusres.2015.10.021_bib0015","unstructured":"ASPR, 2015. Ebola vaccine landscape. United States department of human and human services. <https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CBwQFjAAahUKEwiL3NiFoLbIAhUJBSwKHaP5ApI&url=http%3A%2F%2Fwho.int%2Fmediacentre%2Fevents%2F2015%2FS2.4_Robinson_ebola_MCM_landscape.pdf&usg=AFQjCNGs1rYtcoWjCFDSKxo1WT-VZySBgA&sig2=WYLvEzyAB1dqBD8EwTV8FA&bvm=bv.104819420,d.d24\/> (accessed 9.10.15.)."},{"key":"10.1016\/j.virusres.2015.10.021_sbref0020","article-title":"One step closer to an Ebola virus vaccine","author":"Bausch","year":"2014","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.virusres.2015.10.021_oref0020","unstructured":"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMe1414305\/> (accessed 9.10.15.)."},{"key":"10.1016\/j.virusres.2015.10.021_bib0025","unstructured":"Bavarian Nordic, 2015. Bavarian Nordic announces initiation of phase 1 clinical trial for the Ebola vaccine regimen of MVA-BN Filo and Janssen\u2019s AdVac technology. <http:\/\/www.bavarian-nordic.com\/investor\/news\/news.aspx?news=4556\/> (accessed 9.10.15.)."},{"key":"10.1016\/j.virusres.2015.10.021_bib0030","doi-asserted-by":"crossref","first-page":"g7348","DOI":"10.1136\/bmj.g7348","article-title":"Ebola virus disease","volume":"349","author":"Beeching","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.virusres.2015.10.021_bib0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1242\/dmm.000471","article-title":"Disease modelling for Ebola and Marburg viruses","volume":"2","author":"Bente","year":"2009","journal-title":"Dis. Models Mech."},{"key":"10.1016\/j.virusres.2015.10.021_bib0040","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/1060028014561227","article-title":"Potential and emerging treatment options for Ebola virus disease","volume":"49","author":"Bishop","year":"2015","journal-title":"Ann. Pharmacother."},{"issue":"5","key":"10.1016\/j.virusres.2015.10.021_bib0045","doi-asserted-by":"crossref","first-page":"e1003389","DOI":"10.1371\/journal.ppat.1003389","article-title":"Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with Rabies virus based bivalent vaccine","volume":"9","author":"Blaney","year":"2013","journal-title":"PLoS Pathog."},{"issue":"20","key":"10.1016\/j.virusres.2015.10.021_bib0050","doi-asserted-by":"crossref","first-page":"10605","DOI":"10.1128\/JVI.00558-11","article-title":"Inactivated or live- attenuated bivalent vaccines that confer protection against Rabies and Ebola viruses","volume":"85","author":"Blaney","year":"2011","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virusres.2015.10.021_bib0055","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.virol.2008.09.030","article-title":"Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge","volume":"383","author":"Bukreyev","year":"2009","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.virusres.2015.10.021_bib0060","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1128\/JVI.00105-07","article-title":"Successful tropical respiratory tract immunization of primates against Ebola virus","volume":"81","author":"Bukreyev","year":"2007","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.virusres.2015.10.021_bib0065","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/JVI.80.5.2267-2279.2006","article-title":"A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge","volume":"80","author":"Bukreyev","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2015.10.021_bib0070","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00705-013-1846-9","article-title":"Discussions and decisions of the 2012\u20132014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae study group, January 2012\u2013June 2013","volume":"159","author":"Bukreyev","year":"2014","journal-title":"Arch. Virol."},{"key":"10.1016\/j.virusres.2015.10.021_bib0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/513013a","article-title":"Ebola drug trials set to begin amid crises","volume":"513","author":"Butler","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.virusres.2015.10.021_bib0080","article-title":"West Afica: economic implications of Ebola outbreak for affected countries","author":"Cheto","year":"2014","journal-title":"Teneo Intelligence"},{"issue":"10","key":"10.1016\/j.virusres.2015.10.021_bib0085","first-page":"329","article-title":"Ebola in West Africa: implications on community interaction in urban Nigeria","volume":"2","author":"Chigbu","year":"2014","journal-title":"Int. J. Educ. Res."},{"issue":"8","key":"10.1016\/j.virusres.2015.10.021_bib0090","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1021\/mp500646d","article-title":"A single dose respiratory recombinant Adenovirus-based vaccine provided long-term protection for non-human primates from lethal Ebola infection","volume":"12","author":"Choi","year":"2015","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.virusres.2015.10.021_bib0095","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1128\/JVI.01911-06","article-title":"Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations","volume":"81","author":"Clarke","year":"2007","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.virusres.2015.10.021_bib0100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3855\/jidc.6197","article-title":"Ebola from emergence to epidemic: the virus and the disease, global preparedness and perspectives","volume":"9","author":"Dhama","year":"2015","journal-title":"J. Infect. Dev. Countries"},{"issue":"3","key":"10.1016\/j.virusres.2015.10.021_bib0105","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1128\/AAC.50.3.984-993.2006","article-title":"VP 35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice","volume":"50","author":"Enterlein","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.virusres.2015.10.021_bib0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/erv.10.152","article-title":"Progress in filovirus vaccine development: evaluating the potential for clinical use","volume":"10","author":"Falzarano","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.virusres.2015.10.021_bib0115","first-page":"677","article-title":"Ebola virus: from discovery to vaccine","author":"Feldmann","year":"2003","journal-title":"Nat. Rev."},{"issue":"1","key":"10.1016\/j.virusres.2015.10.021_bib0120","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1371\/journal.ppat.0030002","article-title":"Effective post-exposure treatment of Ebola infection","volume":"3","author":"Feldmann","year":"2007","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virusres.2015.10.021_bib0125","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(10)60667-8","article-title":"Ebola haemorrhagic fever","volume":"377","author":"Feldmann","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.virusres.2015.10.021_bib0130","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3390\/v4091619","article-title":"Potential vaccines and post-exposure treatments for filovirus infections","volume":"4","author":"Friedrich","year":"2012","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.virusres.2015.10.021_bib0135","doi-asserted-by":"crossref","first-page":"749","DOI":"10.7326\/M14-1904","article-title":"Ebola vaccination: if not now, when?","volume":"161","author":"Galvani","year":"2014","journal-title":"Ann. Intern. Med."},{"issue":"11","key":"10.1016\/j.virusres.2015.10.021_bib0140","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1128\/JVI.00456-08","article-title":"Recombinant vesicular stomatitis virus vector mediates post exposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates","volume":"82","author":"Geisbert","year":"2008","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.virusres.2015.10.021_bib0145","doi-asserted-by":"crossref","first-page":"e1000225","DOI":"10.1371\/journal.ppat.1000225","article-title":"Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates","volume":"4","author":"Geisbert","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virusres.2015.10.021_bib0150","doi-asserted-by":"crossref","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections","volume":"204","author":"Geisbert","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virusres.2015.10.021_bib0155","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(10)60357-1","article-title":"Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study","volume":"375","author":"Geisbert","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.virusres.2015.10.021_bib0160","unstructured":"Geo-Vax Lab Inc., 2014. GeoVax announces initiation of Ebola vaccine development program. GeoVax <http:\/\/www.geovax.com\/news-events\/entry\/2014\/10\/02\/geovax-announces-initiation-of-ebola-vaccine-development-program.html\/> (accessed 9.10.15.)."},{"issue":"39","key":"10.1016\/j.virusres.2015.10.021_bib0165","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1016\/j.vaccine.2013.03.020","article-title":"Clinical development of modified vaccinia virus Ankara vaccine","volume":"31","author":"Gibert","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2015.10.021_bib0170","unstructured":"Greffex, Inc., 2014. A trivalent Ebola-Marburg vaccine constructed as a final generation fully deleted Adenovirus vectored. <https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CBwQFjAAahUKEwjIyMTWkLnIAhUFSBQKHc1xAWo&url=http%3A%2F%2Fwww.greffex.com%2Fwp-content%2FEbolaAdVaccineWP102014WEB.pdf&usg=AFQjCNG91RNVT5j2\u00d7267Hivp6OebwK-_ow&sig2=rmWX8f173N532-jcBqpPRw\/> (accessed 9.10.15.)."},{"key":"10.1016\/j.virusres.2015.10.021_bib0175","doi-asserted-by":"crossref","first-page":"S785","DOI":"10.1093\/infdis\/jir298","article-title":"Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany","volume":"204","author":"Gunther","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.virusres.2015.10.021_bib0180","doi-asserted-by":"crossref","first-page":"e1000904","DOI":"10.1371\/journal.ppat.1000904","article-title":"Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebola virus species","volume":"6","author":"Hensley","year":"2010","journal-title":"PLoS Pathog."},{"issue":"9","key":"10.1016\/j.virusres.2015.10.021_bib0185","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1128\/JVI.03361-12","article-title":"Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with Ebola virus","volume":"87","author":"Herbert","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2015.10.021_bib0190","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12915-014-0080-6","article-title":"Ebola virus in West Africa, and the use of experimental therapies or vaccines","volume":"12","author":"Hoenen","year":"2014","journal-title":"BMC Biol."},{"issue":"7","key":"10.1016\/j.virusres.2015.10.021_bib0195","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1517\/14712598.2012.685152","article-title":"Current Ebola vaccines","volume":"12","author":"Hoenen","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.virusres.2015.10.021_bib0200","unstructured":"HUG, 2014. Tested at the University of Geneva, the Canadian experimental Ebola vaccine is well tolerated by volunteers. University of Geneva press release 2 December 2014. <https:\/\/www.google.com.ng\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CBsQFjAAahUKEwjSnNK0k7nIAhVE1xQKHROfDgo&url=http%3A%2F%2Fwww.hug-ge.ch%2Fsites%2Finterhug%2Ffiles%2Fpresse%2Fcommunique_vaccin_ebola_2_12_2014_anglais.pdf&usg=AFQjCNFfuP4iOYLA8lPAxR4-j-Xtt-nMeQ&bvm=bv.104819420,d.d24\/> (accessed 9.10.15)."},{"issue":"1","key":"10.1016\/j.virusres.2015.10.021_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.06.006","article-title":"Vaccinia virus vaccines: past, present and future","volume":"84","author":"Jacobs","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virusres.2015.10.021_bib0210","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp1412166","article-title":"Ebola vaccine\u2014an urgent international priority","author":"Kanapathipillai","year":"2014","journal-title":"New Engl. J. Med."},{"issue":"9977","key":"10.1016\/j.virusres.2015.10.021_bib0215","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(14)62385-0","article-title":"Safety and innunogencity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Uganda adults: a phase 1b, randomized double-blind, placebo-controlled chemical trial","volume":"385","author":"Kibuuka","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.virusres.2015.10.021_bib0220","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.virol.2005.10.042","article-title":"Chimpanzee adenovirus vaccine protects against Zaire Ebola virus","volume":"346","author":"Kobinger","year":"2006","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.virusres.2015.10.021_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/fmb.11.110","article-title":"Ebola virus: a brief review of novel therapeutic targets","volume":"7","author":"Kondratowicz","year":"2012","journal-title":"Future Microbiol."},{"key":"10.1016\/j.virusres.2015.10.021_bib0230","doi-asserted-by":"crossref","first-page":"S810","DOI":"10.1093\/infdis\/jir299","article-title":"Basic clinical and laboratory features of filoviral hemorrhagic fever","volume":"204","author":"Kortepeter","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.virusres.2015.10.021_bib0235","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomized, double-blind phase 1\/2a clinical trial","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virusres.2015.10.021_bib0240","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/2049-9957-3-43","article-title":"Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus","volume":"3","author":"Lai","year":"2014","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.virusres.2015.10.021_bib0245","first-page":"1","article-title":"Chimpanzee Adenovirus vector Ebola vaccine-preliminary report","author":"Ledgerwood","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2015.10.021_bib0250","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1473-3099(15)00222-4","article-title":"Use of low dose rVSV-ZEBOV: safety issues in a Swiss cohort","volume":"15","author":"Ledgerwood","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.virusres.2015.10.021_bib0255","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nsmb.1765","article-title":"Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35","volume":"17","author":"Leung","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.virusres.2015.10.021_bib0260","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0140-6736(80)92352-1","article-title":"Inactivated vaccine for Ebola virus efficacious in guinea pig model","author":"Lupton","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.virusres.2015.10.021_bib0265","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009872","article-title":"Emerging viral disease: confronting threats with new technologies","volume":"6","author":"Marston","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.virusres.2015.10.021_bib0270","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/CVI.00162-06","article-title":"A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial","volume":"13","author":"Martin","year":"2006","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.virusres.2015.10.021_bib0275","doi-asserted-by":"crossref","first-page":"S825","DOI":"10.1093\/infdis\/jir295","article-title":"Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles","volume":"204","author":"Martinez","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virusres.2015.10.021_bib0280","doi-asserted-by":"crossref","first-page":"S1066","DOI":"10.1093\/infdis\/jir348","article-title":"Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy","volume":"204","author":"Marzi","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.virusres.2015.10.021_bib0285","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"100","author":"Marzi","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.virusres.2015.10.021_bib0290","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-1702(02)00338-6","article-title":"Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs","volume":"92","author":"Mellquist-Riemenschneider","year":"2003","journal-title":"Virus Res."},{"issue":"8","key":"10.1016\/j.virusres.2015.10.021_bib0295","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1172\/JCI81532","article-title":"Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses","volume":"125","author":"Meyer","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.virusres.2015.10.021_bib0300","doi-asserted-by":"crossref","first-page":"e94355","DOI":"10.1371\/journal.pone.0094355","article-title":"Durability of a vesicular stomatitis virus-based Marburg virus vaccine in nonhuman primates","volume":"9","author":"Mire","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.virusres.2015.10.021_bib0305","doi-asserted-by":"crossref","first-page":"e2600","DOI":"10.1371\/journal.pntd.0002600","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus","volume":"7","author":"Mire","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.virusres.2015.10.021_bib0310","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nature14428","article-title":"Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus","volume":"520","author":"Mire","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.virusres.2015.10.021_bib0315","series-title":"Novel Technologies for Vaccine Development","first-page":"33","article-title":"Viral-vectored vaccines to control pathogenic filoviruses","author":"Mire","year":"2014"},{"issue":"1","key":"10.1016\/j.virusres.2015.10.021_bib0320","doi-asserted-by":"crossref","first-page":"e1567","DOI":"10.1371\/journal.pntd.0001567","article-title":"Recombinant vesicular stomatitis vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates","volume":"6","author":"Mire","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.virusres.2015.10.021_bib0325","unstructured":"Norwegian Institute of Public Health, 2014. Discussion note for the WHO urgent Ebola vaccine access meeting. Norwegian Institute of Public Health. <https:\/\/www.google.com.ng\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CBsQFjAAahUKEwimypH26brIAhXCuhoKHS5-DQ4&url=http%3A%2F%2Fnews.sciencemag.org%2Fsites%2Fdefault%2Ffiles%2FNorway_submission_WHO_EVD_23Oct2014.pdf&usg=AFQjCNGtGDTO6ENMcyYqK6Y6-dszqstwCA\/> (accessed 9.10.2015.)."},{"issue":"1","key":"10.1016\/j.virusres.2015.10.021_bib0330","doi-asserted-by":"crossref","first-page":"11","DOI":"10.9734\/IJMPCR\/2015\/16632","article-title":"How the spread of Ebola virus was curtailed in Nigeria","volume":"4","author":"Ohimain","year":"2015","journal-title":"Int. J. Med. Pharm. Case Rep."},{"issue":"22","key":"10.1016\/j.virusres.2015.10.021_bib0335","doi-asserted-by":"crossref","first-page":"14189","DOI":"10.1128\/JVI.79.22.14189-14196.2005","article-title":"Protective cytotoxic T-cell responses induced by Venezuelan equine encephalitis virus replicons expressing Ebola virus proteins","volume":"79","author":"Olinger","year":"2005","journal-title":"J. Virol."},{"issue":"44","key":"10.1016\/j.virusres.2015.10.021_bib0340","doi-asserted-by":"crossref","first-page":"18030","DOI":"10.1073\/pnas.1213709109","article-title":"Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques","volume":"109","author":"Olinger","year":"2012","journal-title":"PNA"},{"issue":"9","key":"10.1016\/j.virusres.2015.10.021_bib0345","first-page":"184","article-title":"Ebola outbreak in Africa: current issues\u2014a mini review","volume":"2","author":"Onwuakor","year":"2014","journal-title":"Am. J. Med. Case Rep."},{"key":"10.1016\/j.virusres.2015.10.021_bib0350","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1016\/j.vaccine.2012.07.073","article-title":"Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein","volume":"30","author":"Papaneri","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2015.10.021_bib0355","doi-asserted-by":"crossref","first-page":"S413","DOI":"10.1086\/520603","article-title":"Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice","volume":"196","author":"Patel","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virusres.2015.10.021_bib0360","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/smvy.1994.1015","article-title":"Filoviruses as emerging pathogens","volume":"5","author":"Peters","year":"1994","journal-title":"Semi. Virol."},{"key":"10.1016\/j.virusres.2015.10.021_bib0365","unstructured":"PHAC, 2014. Canada\u2019s Ebola vaccine. Public Health Agency of Canada. <http:\/\/www.phac-aspc.gc.ca\/id-mi\/vsv-ebov-fs-eng.php\/> (accessed 9.10.2015.)."},{"issue":"51","key":"10.1016\/j.virusres.2015.10.021_bib0370","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1073\/pnas.1117715108","article-title":"A non replicating subunit vaccine protect mice against lethal Ebola virus challenge","volume":"108","author":"Phoolcharoen","year":"2011","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.virusres.2015.10.021_bib0375","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1128\/CVI.00467-09","article-title":"Protection of nonhuman primates against two species of EBOLA virus infection with a single complex Adenovirus vector","volume":"17","author":"Pratt","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"issue":"39","key":"10.1016\/j.virusres.2015.10.021_bib0380","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1016\/j.vaccine.2013.03.017","article-title":"Modified vaccinia Ankara: inate immune activation and induction of cellular signaling","volume":"31","author":"Price","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.virusres.2015.10.021_bib0385","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0264-410X(00)00113-4","article-title":"Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus","volume":"19","author":"Pushko","year":"2000","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.virusres.2015.10.021_bib0390","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1128\/JVI.75.23.11677-11685.2001","article-title":"Individual and bivalent vaccines based on Alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses","volume":"75","author":"Pushko","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2015.10.021_bib0395","doi-asserted-by":"crossref","DOI":"10.1038\/srep03365","article-title":"Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb","volume":"3","author":"Qiu","year":"2013","journal-title":"Sci. Rep."},{"issue":"138","key":"10.1016\/j.virusres.2015.10.021_bib0400","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003876","article-title":"Successful treatment of Ebola virus ?infected cynomolgus macaques with monoclonal antibodies","volume":"4","author":"Qiu","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"18","key":"10.1016\/j.virusres.2015.10.021_bib0405","doi-asserted-by":"crossref","first-page":"9176","DOI":"10.1128\/JVI.76.18.9176-9185.2002","article-title":"Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4+ T cells","volume":"76","author":"Rao","year":"2002","journal-title":"J. Virol."},{"issue":"24","key":"10.1016\/j.virusres.2015.10.021_bib0410","doi-asserted-by":"crossref","first-page":"13469","DOI":"10.1128\/JVI.01097-07","article-title":"Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1","volume":"81","author":"Reid","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2015.10.021_bib0415","doi-asserted-by":"crossref","first-page":"S1060","DOI":"10.1093\/infdis\/jir347","article-title":"Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection","volume":"204","author":"Reynard","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.virusres.2015.10.021_bib0420","doi-asserted-by":"crossref","first-page":"439","DOI":"10.4161\/hv.6.6.11097","article-title":"Recent advances in Ebola virus vaccines development","volume":"6","author":"Richardson","year":"2010","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.virusres.2015.10.021_bib0425","first-page":"007","article-title":"Evaluation of different strategies for post-exposure treatment of Ebola virus infection in rodents","volume":"S1","author":"Richardson","year":"2011","journal-title":"J. Bioterror. Biodef."},{"issue":"4","key":"10.1016\/j.virusres.2015.10.021_bib0430","doi-asserted-by":"crossref","first-page":"e5308","DOI":"10.1371\/journal.pone.0005308","article-title":"Enhanced protection against Ebola virus mediated by an improved Adenovirus-based vaccine","volume":"4","author":"Richardson","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.virusres.2015.10.021_bib0435","unstructured":"Salaam-Blyther, T., 2014. US and international health responses to the Ebola outbreak in West Africa Congressional research service. <https:\/\/www.google.com.ng\/url?.sa=t&rct=j&q=&esrc=s&source=web&cd=3&cad=rja&uact=8&ved=0CCcQFjACahUKEwjloOzC8brIAhXKVxoKHd7nDk8&url=http%3A%2F%2Ffpc.state.gov%2Fdocuments%2Forganization%2F231281.pdf&usg=AFQjCNEGh52HqhB4QjRVxd1b6GOlEO0G5w&bvm=bv.104819420,d.d24\/> (accessed 9.10.15.)."},{"issue":"4","key":"10.1016\/j.virusres.2015.10.021_bib0440","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/infdis\/jiu511","article-title":"Safety and immunogenicity of DNA vaccines encoding Ebola virus and Marburg wild-type glycoproteins in a phase I clinical trial?","volume":"211","author":"Sarwar","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.virusres.2015.10.021_bib0445","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/mt.2013.61","article-title":"Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola","volume":"21","author":"Shedlock","year":"2013","journal-title":"Mol. Ther."},{"issue":"39","key":"10.1016\/j.virusres.2015.10.021_bib0450","first-page":"867","article-title":"Ebola virus disease outbreak-Nigeria, July\u2013September 2014","volume":"63","author":"Shuaib","year":"2014","journal-title":"Morb. Mortal. Wkly. Rep."},{"issue":"2","key":"10.1016\/j.virusres.2015.10.021_bib0455","first-page":"201","article-title":"Viral vaccines and vectors-some lessons from cytomegaloviruses","volume":"114","author":"Skenderi","year":"2012","journal-title":"Period. Biol."},{"key":"10.1016\/j.virusres.2015.10.021_bib0460","unstructured":"Smith, G., 2014. Novavax annunouces Ebola vaccines development programme at the 8th vaccine and ISV conference, Philadelphia. <http:\/\/ir.novavax.com\/phoenix.zhtml?c=71178&p=irol-newsArticle&ID=1981603\/> (accessed 9.10.15.)."},{"key":"10.1016\/j.virusres.2015.10.021_bib0465","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/vaccines1040398","article-title":"Clinical development of a cytomegalovirus DNA vaccine: from product concept to pivotal phase 3 trial","volume":"1","author":"Smith","year":"2013","journal-title":"Vaccines"},{"issue":"11","key":"10.1016\/j.virusres.2015.10.021_bib0470","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1128\/CVI.00363-12","article-title":"Profiling the native specific human humoral immune response to Sudan Ebola virus strain gulu by chemiluminescence enzyme-linked immunosorbent assay","volume":"19","author":"Sobarzo","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"issue":"10","key":"10.1016\/j.virusres.2015.10.021_bib0475","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against Ebola virus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat. Med."},{"issue":"6812","key":"10.1016\/j.virusres.2015.10.021_bib0480","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/35046108","article-title":"Development of a preventive vaccine for Ebola virus infection in primates","volume":"408","author":"Sullivan","year":"2000","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.virusres.2015.10.021_bib0485","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1371\/journal.pmed.0030177","article-title":"Immune protection of nonhuman primates against Ebola virus with single low-dose Adenovirus vectors encoding modified GPs","volume":"3","author":"Sullivan","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.virusres.2015.10.021_bib0490","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nature01876","article-title":"Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates","volume":"424","author":"Sullivan","year":"2003","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.virusres.2015.10.021_bib0495","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/CVI.00431-07","article-title":"Vaccine to confer to nonhuman primates complete protection against Multistrain Ebola and Marburg virus infections","volume":"15","author":"Swenson","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"issue":"2","key":"10.1016\/j.virusres.2015.10.021_bib0500","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1128\/JVI.77.2.1069-1074.2003","article-title":"Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses","volume":"77","author":"Takada","year":"2003","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.virusres.2015.10.021_bib0505","first-page":"11","article-title":"Psycho social implication of infiltration of Ebola virus disease into Nigeria: religious and counselling perspective","volume":"3","author":"Tayo","year":"2015","journal-title":"Eur. J. Res. Soc. Sci."},{"key":"10.1016\/j.virusres.2015.10.021_bib0510","unstructured":"The Economist, 2015. Ebola graphics: the toll of tragedy. The Economist January 2015. <http:\/\/www.economist.com\/blogs\/graphicdetail\/2015\/08\/ebola-graphics?page=1&fsrc=rss\/> (accessed 9.10.15.)."},{"issue":"July (2)","key":"10.1016\/j.virusres.2015.10.021_bib0515","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.virol.2013.03.013","article-title":"The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals","volume":"441","author":"Trunschke","year":"2013","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.virusres.2015.10.021_bib0520","doi-asserted-by":"crossref","first-page":"e1275","DOI":"10.1371\/journal.pntd.0001275","article-title":"A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL Epitope confers protection against Ebola virus","volume":"5","author":"Tsuda","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.virusres.2015.10.021_bib0525","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/vaccines2040785","article-title":"DNA vaccines: recent developments and the future","volume":"2","author":"Wahren","year":"2014","journal-title":"Vaccines"},{"issue":"6","key":"10.1016\/j.virusres.2015.10.021_bib0530","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1128\/JVI.80.6.2738-2746.2006","article-title":"Development of a cAdVax-based bivalent Ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus","volume":"80","author":"Wang","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2015.10.021_bib0535","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.virusres.2014.06.001","article-title":"A highly immunogenic fragment derived from Zaire Ebola virus glycoprotein elicits effective neutralizing antibody","volume":"189","author":"Wang","year":"2014","journal-title":"Virus Res."},{"key":"10.1016\/j.virusres.2015.10.021_bib0540","doi-asserted-by":"crossref","first-page":"S1053","DOI":"10.1093\/infdis\/jir346","article-title":"Advances in virus-like particle vaccine for Filoviruses","volume":"204","author":"Warfield","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virusres.2015.10.021_bib0545","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1086\/520612","article-title":"Filovirus like particles produced in insect cells: immunogenicity and protection in rodents","volume":"196","author":"Warfield","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virusres.2015.10.021_bib0550","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1086\/520583","article-title":"Ebola virus-like particle-based vaccine protects nonhuman primatesaginst lethal Ebola virus challenge","volume":"196","author":"Warfield","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virusres.2015.10.021_bib0555","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1086\/520582","article-title":"Ebola virus (EBOV) VP24 inhibits transcription and replication of the EBOV genome","volume":"196","author":"Watanabe","year":"2007","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.virusres.2015.10.021_bib0560","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1128\/JVI.78.2.999-1005.2004","article-title":"Production of novel Ebola vaccine-like particles from cDNAs: an alternative to Ebola virus generation by reverse genetics","volume":"78","author":"Watanabe","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2015.10.021_bib0565","series-title":"Background Document Potential Ebola Therapies and Vaccines","author":"WHO","year":"2014"},{"key":"10.1016\/j.virusres.2015.10.021_bib0570","series-title":"Potential Ebola therapies and vaccines","author":"WHO","year":"2014"},{"key":"10.1016\/j.virusres.2015.10.021_bib0575","series-title":"New therapeutics and preventive medicines to fight the Ebola epidemic","author":"WHO","year":"2014"},{"key":"10.1016\/j.virusres.2015.10.021_bib0580","series-title":"Ebola Situation report 19 August 2015","author":"WHO","year":"2015"},{"key":"10.1016\/j.virusres.2015.10.021_bib0585","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJMoa1411100","article-title":"Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections","volume":"371","author":"WHO Ebola Response Team","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2015.10.021_bib0590","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1006\/viro.2001.1012","article-title":"Vaccine potential of Ebola virus VP24, VP30, VP 35, and VP40 proteins","volume":"286","author":"Wilson","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2015.10.021_bib0595","unstructured":"World Bank, 2014. The economic impact of the 2014 Ebola epidemic: short and medium term estimate for Guinea, Liberia and Sierra Leone. Report no. 90748. http:\/\/www.worldbank.org\/en\/region\/afr\/publication\/the-economic-impact-of-the-2014-ebola-epidemic-short-and-medium-term-estimates-for-west-africa (accessed 27.10.15.)."},{"issue":"43","key":"10.1016\/j.virusres.2015.10.021_bib0600","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1016\/j.vaccine.2014.08.028","article-title":"Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents","volume":"32","author":"Wong","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.virusres.2015.10.021_bib0605","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/1074-7613(94)90074-4","article-title":"MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant Adenoviruses","volume":"1","author":"Yang","year":"1994","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.virusres.2015.10.021_bib0610","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1128\/JVI.69.4.2004-2015.1995","article-title":"Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses","volume":"69","author":"Yang","year":"1995","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.virusres.2015.10.021_bib0615","first-page":"412","article-title":"Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver","volume":"3","author":"Yang","year":"1996","journal-title":"Gene Ther."},{"issue":"2","key":"10.1016\/j.virusres.2015.10.021_bib0620","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.virol.2008.04.029","article-title":"A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals","volume":"377","author":"Yang","year":"2008","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.virusres.2015.10.021_bib0625","article-title":"The 2014 Ebola virus outbreak in West Africa: current perspectives for prevention and treatment","volume":"1","author":"Yelle","year":"2014","journal-title":"J. Hum. Virol. Retrovirol."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170215301003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170215301003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T05:31:36Z","timestamp":1599715896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170215301003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":126,"alternative-id":["S0168170215301003"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2015.10.021","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the development of vaccines for Ebola virus disease","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2015.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}